Clinical trials: Major Depressive Episode
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder, Bipolar I Disorder
Digital Phenotypes for Predicting Depression_Validation
This 12-month, single-site prospective observational study will prospectively monitor the recurrence of mood episodes while continuously collecting passive digital phenotypes in individuals with and without mood disorders.
- Conditions
- Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder, Mood Disorders
- Trial name
- NCT07880015
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Depression - Major Depressive Disorder
Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms…
- Trial name
- NCT07480525
- Testing
- Escitalopram (Oral antidepressant)
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Peking University
Depression Chronic, Depression and Quality of Life
Remote Medical Monitoring of Patients With Depression
The goal of this clinical trial is to learn if ThIA Suivi, a digital tool for remote monitoring of patients, can improve the care of adults with depression who are followed by a psychiatrist.
- Conditions
- Depression Chronic, Depression and Quality of Life, Depression, Major Depressive Episode
- Trial name
- TELEMED-DEP (NCT07878754)
- Testing
- Use of ThIA Medical Device
- Where
- 3 sites in France
- Volunteers
- 608 people
- Sponsor
- ThIA Santé Mentale
Long COVID, Major Depressive Disorder
Presynaptic Imaging in Major Depressive Episodes After COVID-19
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP).
- Conditions
- Long COVID, Major Depressive Disorder, Major Depressive Episode
- Trial name
- PCOV (NCT06086366)
- Testing
- [11C]DTBZ PET scan, [18F]SDM8 PET scan, MRI scan
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-100 in Bipolar Disorder With Depression (BD-D)
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used…
- Trial name
- NCT06656416
- Testing
- ALTO-100
- Where
- 68 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Alto Neuroscience
Major Depressive Episode, Depression - Major Depressive Disorder
Personalized Ultrasonic Brain Stimulation for Depression (R61)
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation…
- Conditions
- Major Depressive Episode, Depression - Major Depressive Disorder, Treatment-Resistant Major Depressive Disorder
- Trial name
- NCT06902298
- Testing
- LTFUS to SCC, LTFUS to ALIC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Mickey
Major Depression
Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression
This study is evaluating the safety and feasibility of the novel deep TMS H-coil designs in the treatment of resistant major depression in an open study using two different H-coil designs.
- Trial name
- NCT00445237
- Testing
- H1 and H2 deep TMS coils
- Where
- Israel
- Sponsor
- Shalvata Mental Health Center
Depressive Disorder, Major
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
- Trial name
- NCT00186498
- Testing
- memantine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Major Depressive Disorder (MDD)
Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode
The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from…
- Trial name
- EMC1 (NCT06601140)
- Testing
- EMOCARE software
- Where
- 11 sites in France
- Volunteers
- 104 people
- Sponsor
- Emobot
Bipolar Disorder (BD), Major Depressive Episode (MDE)
Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder
The goal of this interventional clinical trial is to assess the diagnostic performance of a composite diagnostic medical devise based on blood-based in vitro diagnostic device and Mood Disorder Questionnaire (MDQ) in identifying…
- Conditions
- Bipolar Disorder (BD), Major Depressive Episode (MDE), Primary Care, Major Depression
- Trial name
- BIPOVITE (NCT07031817)
- Testing
- Venous blood sample for measuring blood biomarkers related to bipolar disorder, Standardized psychiatric assessment tools
- Where
- France
- Volunteers
- 623 people
- Sponsor
- University Hospital, Montpellier
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Relevance of a Telemedicine Monitoring in the Management of Depression
Major depressive disorder (MDD) is a common chronic disease. It is the main cause of morbidity and disability in the world with, among other things, an increase in cardio-metabolic risk and a reduction in life expectancy…
- Trial name
- TELEDEP (NCT06076317)
- Testing
- Telemedicine session
- Where
- France
- Volunteers
- 836 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Episode
Depressive Symptoms and Subjective Stress in the Course of the Menstrual Cycle - an Ambulatory Assessment Study.
Background: Major changes in female sex hormone concentrations influence the development of depressive symptoms in women. This hypothesis has been thoroughly investigated with regard to the menopause, the postpartal phase and…
- Trial name
- DepCy (NCT04086316)
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Freie Universität Berlin
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depression, Bipolar Disorder
Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
The goal of this project is to study the course and outcome of illness in individuals who present with a first episode of depression or mania, or who have a recurrent disorder but have never received treatment.
- Trial name
- NCT01529905
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- McMaster University
Major Depressive Episode
A Text Messaging Intervention to Reduce Perinatal Depression Risk
Development and preliminary testing of a text messaging intervention that will reduce the risk of a major depressive episode and worsening depressive symptoms in perinatal individuals.
- Trial name
- PTMI (NCT06117397)
- Testing
- Text Messaging Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Massachusetts, Worcester
Depression, Major Depressive Disorder
Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)
Transcranial Light Therapy involves non-invasive and invisible beams of light that increase energy metabolism in the brain. Transcranial light therapy has been found to promote brain metabolism which may help people with…
- Trial name
- ELATED-3 (NCT02959307)
- Testing
- Transcranial Light Therapy
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorders
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
- Trial name
- NCT00825058
- Testing
- amibegron (SR58611A), paroxetine
- Where
- 8 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Major Depressive Episode
Predict MDE Outcomes After MST
This trial attempts to explore the treatment outcome of magnetic seizure therapy (MST) for major depressive episode. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).
- Trial name
- NCT03841019
- Testing
- Magpro X100 + Option, ThymatronSystem Ⅳ Electroconvulsive System
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Mental Health Center